HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

SB 657510

a urotensin II antagonist

Also Known As:

SB-657510; SB657510

Networked: 4 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amides: 2428
  - Sulfonamides: 2809
    - SB 657510: 4
- Sulfur Compounds: 278
  - Sulfones: 534
    - Sulfonamides: 2809
      - SB 657510: 4

Experts

1.	Schwertani, Adel: 2 articles (09/2016 - 03/2014)
2.	Hao, Ting: 1 article (01/2017)
3.	Li, Jing: 1 article (01/2017)
4.	Wang, Dan: 1 article (01/2017)
5.	Wang, Yu: 1 article (01/2017)
6.	Wu, Yu-Qing: 1 article (01/2017)
7.	Zhao, Pan-Pan: 1 article (01/2017)
8.	Zhou, Cheng-Hua: 1 article (01/2017)
9.	Zhu, Yang-Zi: 1 article (01/2017)
10.	Echavarria, Raquel: 1 article (09/2016)

Related Diseases

1.	Weight Gain 03/01/2014 - "Treatment of ob/ob mice with the UII receptor antagonist SB657510 significantly improved glucose levels, blood pressure, hyperlipidemia, expression of myocardial SERCA2a, intracellular Na(+) and Ca(2+) and cardiac function in association with a decrease in weight gain, and mammalian target of rapamycin (mTOR) and sodium/hydrogen exchanger 1 (NHE-1) protein expression compared with vehicle (P<0.05). "
2.	Hyperlipidemias (Hyperlipidemia) 03/01/2014 - "Treatment of ob/ob mice with the UII receptor antagonist SB657510 significantly improved glucose levels, blood pressure, hyperlipidemia, expression of myocardial SERCA2a, intracellular Na(+) and Ca(2+) and cardiac function in association with a decrease in weight gain, and mammalian target of rapamycin (mTOR) and sodium/hydrogen exchanger 1 (NHE-1) protein expression compared with vehicle (P<0.05). "
3.	Neoplasms (Cancer) 09/20/2016 - "In a mouse xenograft model, SB657510 blocked the growth of established ELT3 tumors, reduced the number of circulating tumor cells, and attenuated the production of VEGF-D, a clinical biomarker of LAM. "
4.	Circulating Neoplastic Cells 09/20/2016 - "In a mouse xenograft model, SB657510 blocked the growth of established ELT3 tumors, reduced the number of circulating tumor cells, and attenuated the production of VEGF-D, a clinical biomarker of LAM. "
5.	Inflammation (Inflammations) 07/30/2013 - "Taken together, our results demonstrate that the UII antagonist SB-657510 decreases the progression of inflammation induced by UII in endothelial cells. "

Related Drugs and Biologics

1.	TOR Serine-Threonine Kinases
2.	Proteins (Proteins, Gene)
3.	Glucose (Dextrose)
4.	Sodium-Hydrogen Exchanger 1
5.	Vascular Endothelial Growth Factor D
6.	Biomarkers (Surrogate Marker)
7.	lipoarabinomannan (LAM)

Related Therapies and Procedures

1.	Spinal Injections